PT  - JOURNAL ARTICLE
AU  - Matthew Moll
AU  - Sharon M. Lutz
AU  - Auyon J Ghosh
AU  - Phuwanat Sakornsalkopat
AU  - International COPD Genetics Consortium
AU  - Craig Hersh
AU  - Terri H Beaty
AU  - Frank Dudbridge
AU  - Martin D Tobin
AU  - Murray A Mittleman
AU  - Edwin K. Silverman
AU  - Brian D. Hobbs
AU  - Michael H. Cho
TI  - Relative Contributions of Family History and a Polygenic Risk Score on COPD and Related Outcomes: COPDGene and ECLIPSE studies
AID  - 10.1101/2020.07.23.20160739
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.23.20160739
4099  - http://medrxiv.org/content/early/2020/07/24/2020.07.23.20160739.short
4100  - http://medrxiv.org/content/early/2020/07/24/2020.07.23.20160739.full
AB  - Introduction Family history is a risk factor for chronic obstructive pulmonary disease (COPD). We previously developed a COPD risk score from genome-wide genetic markers (polygenic risk score, or PRS). Whether the PRS and family history provide complementary or redundant information for predicting COPD and related outcomes is unknown.Methods We assessed the predictive capacity of family history and PRS on COPD and COPD-related outcomes in European ancestry subjects from the COPDGene and ECLIPSE studies. We also performed interaction and mediation analyses.Results In COPDGene, family history and PRS were significantly associated with COPD in a single model (PFamHx = 1.6e-12; PPRS = 5.0e-92). Similar trends were seen in ECLIPSE. Area-under-the-receiver-operator-characteristic-curves (AUCs) for family history, PRS, and the combined predictors for COPD were 0.752, 0.798, and 0.803, respectively. The AUC for a model containing both family history and the PRS was significantly higher than models with PRS (p = 0.00035) or family history (p = 6.1e-29) alone. Both family history and PRS were significantly associated with BODE, SGRQ, and multiple measures of quantitative emphysema and airway thickness. There was a weakly positive interaction between family history and the PRS under the additive, but not the multiplicative scale (RERI = 0.48, p=0.04). Mediation analysis found 16.5% of the effect of family history on risk for COPD was mediated through the PRS [95% CI: 9.4%-24.3%].Conclusion Family history and the PRS provide complementary information for predicting COPD and related outcomes. Future studies can address the impact of obtaining both measures in clinical practice.Competing Interest StatementEKS received grant support from GlaxoSmithKline and Bayer. MHC has received grant support from GlaxoSmithKline and Bayer, consulting fees from Genentech and AstraZeneca, and speaking fees from Illumina. Dr. Hersh reports grant support from Boehringer-Ingelheim, Novartis, Bayer, and Vertex, outside of this study. MDT receives grant support from GlaxoSmithKline and Orion. The other authors declared no conflicts of interest.Funding StatementMM is supported by T32HL007427. BDH is supported by NIH K08HL136928 and R01HL089856. MHC is supported by NIH R01HL137927 and R01HL135142. EKS is supported by NIH R01HL137927, R01HL147148, and P01 HL114501 M.D.T. is supported by a Wellcome Trust Investigator Award (WT202849/Z/16/Z). The research was partially supported by the NIHR Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The ECLIPSE study (NCT00292552; GSK code SCO104960) was funded by GlaxoSmithKline. The COPDGene project (NCT00608764) was supported by R01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. COPD Foundation Funding The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This section describes each study and provides details about measurements and genotyping. All participants gave informed consent and study protocols were approved by local Research Ethics Committees and Institutional Review Boards. COPDGene COPDGene is a multicenter observational study which primarily consists of smokers with and without COPD1. Subjects in COPDGene have at least 10 pack-years of smoking (except for a smaller group of nonsmoking controls, who were excluded from the analyses in this manuscript). Illumina (San Diego, CA) performed genotyping on the HumanOmniExpress array. Genotyping at the Z and S alleles was performed in all subjects. Subjects with severe alpha-1 antitrypsin deficiency were excluded. Imputation was performed the Michigan Imputation Server to the Haplotype Resource Consortium2 and 1000 Genomes Phase I v3 Cosmopolitan reference panels, for whites and African Americans, respectively. Variants with an r2 value of ≤ 0.3 were removed. Family history was obtained by questionnaire, asking as separate questions, whether there was a paternal family history of COPD, chronic bronchitis, or emphysema, and again for maternal family history (6 questions total). ECLIPSE The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study was a case-control study of smokers with ≥ 10 pack years of smoking history, aged 40-75 years, and without other respiratory diseases.3 Genotyping was performed using the Illumina HumanHap 550 V3 (Illumina, San Diego, CA). Subjects and markers with a call rate of < 95% were excluded. Imputation was performed using the Michigan Imputation Server and Haplotype Resource Consortium2 reference panel. Family history was obtained by the American Thoracic Society Division of Lung Disease questionnaire (ATS-DLD-78A), which asked about a paternal or maternal family history of chronic bronchitis or emphysema (4 questions total). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo new data were generated in this study. Weights and R code for polygenic risk scores were previously reported and are publicly available at http://www.copdconsortium.org/announcements/10polygenicriskscorercode. http://www.copdconsortium.org/announcements/10polygenicriskscorercode